Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Merck
UBS
Queensland Health
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Baxter
Accenture

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,994,220

« Back to Dashboard

Which drugs does patent 7,994,220 protect, and when does it expire?

Patent 7,994,220 protects SAVELLA and is included in one NDA.

This patent has thirty-one patent family members in twenty-two countries.
Summary for Patent: 7,994,220
Title:Milnacipran for the long-term treatment of fibromyalgia syndrome
Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.
Inventor(s): Rao; Srinivas G. (Encinitas, CA), Gendreau; Michael (Poway, CA), Kranzler; Jay D. (La Jolla, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:11/535,237
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,994,220

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial MANAGEMENT OF FIBROMYALGIA ➤ Try a Free Trial
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial MANAGEMENT OF FIBROMYALGIA ➤ Try a Free Trial
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial MANAGEMENT OF FIBROMYALGIA ➤ Try a Free Trial
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial MANAGEMENT OF FIBROMYALGIA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,994,220

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006294645 ➤ Try a Free Trial
Brazil PI0617541 ➤ Try a Free Trial
Canada 2624018 ➤ Try a Free Trial
China 101355930 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Baxter
Argus Health
Chubb
Mallinckrodt
McKesson
Fuji
Daiichi Sankyo
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.